StockMarketWire.com - Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC [LON:AZN] and raised its price target to 9300p (from 9200p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk